Search

Your search keyword '"Francesco, Marchesi"' showing total 16 results
Start Over Author "Francesco, Marchesi" Journal hemasphere
16 results on '"Francesco, Marchesi"'

2. S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY

Author

Jon Salmanton-García, Francesco Marchesi, Maria Gomes Da Silva, Francesca Farina, Julio Dávila-Valls, Yavuz M. Bilgin, Andreas Glenthøj, Iker Falces-Romero, Jaap Van Doesum, Jorge Labrador, Caterina Buquicchio, Shaimaa EL-Ashwah, Verena Petzer, Jens VAN Praet, Martin Schönlein, Michelina Dargenio, Gustavo-Adolfo Méndez, Stef Meers, Federico Itri, Antonio Giordano, Laszlo Imre Pinczes, Ildefonso Espigado, Zlate Stojanoski, Alberto Lopez-Garcia, Lucia Prezioso, Ozren Jaksic, Antonio Vena, Nicola Stefano Fracchiolla, Tomas Jose Gonzalez-Lopez, Natasa Čolović, Mario Delia, Barbora Weinbergerová, Monia Marchetti, Joyce Marques DE Almeida, Olimpia Finizio, Caroline Besson, Monika M. Biernat, Toni Valkovic, Tobias Lahmer, Annarosa Cuccaro, Irati Ormazabal Velez, Josip Batinic, Noemí Fernández, Nick de Jonge, Carlo Tascini, Amalia N. Anastasopoulou, Rémy Duléry, Maria Ilaria DEL Principe, Gaëtan Plantefeve, Mario Virgilio Papa, Marcio Nucci, Moraima Carmen Jimenez Balarezo, Avinash Aujayeb, Jose Angel Hernandez Rivas, Maria Merelli, Chiara Cattaneo, Ola Blennow, Anna Nordlander, Alba Cabirta, Gina Varricchio, Maria Vittoria Sacchi, Raul Cordoba, Elena Arellano, Stefanie Gräfe, Dominik Wolf, Ziad Emarah, Emanuele Ammatuna, Ditte Stampe Hersby, Sonia Martín-Pérez, Raquel Nunes Rodrigues, Laman Rahimli, Livio Pagano, and Oliver A. Cornely

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

3. P487: MIDOSTAURIN PLASMA EXPOSURE IN PATIENTS WITH FLT3-MUT ACUTE MYELOID LEUKEMIA UNDERGOING POSACONAZOLE PROPHYLAXIS DURING INDUCTION TREATMENT: A PROSPECTIVE MULTICENTRE STUDY FROM THE SEIFEM GROUP

Author

Francesco Marchesi, Pierantonio Menna, Chiara Cattaneo, Anna Candoni, Mario Delia, Gianpaolo Nadali, Crescenza Pasciolla, Salvatore Perrone, Luisa Verga, Daniele Armiento, Maria Ilaria DEL Principe, Nicola Stefano Fracchiolla, Emanuela Salvatorelli, S Lupisella, Irene Terrenato, Alessandro Busca, and Livio Pagano

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. P478: MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Author

Giorgia Silvestrini, Tiziana Ottone, Rocco Giovanni Piazza, Serena Travaglini, Carmelo Gurnari, Francesco Marchesi, Anna Maria Nardozza, Emiliano Fabiani, Enrico Attardi, Mariadomenica Divona, Paola Ricci, Maria Antonietta Irno Consalvo, Sara Ienzi, Roberto Arcese, Annalisa Biagi, Luciano Fiori, Mariangela Novello, Alessandro Mauriello, Adriano Venditti, Lucia Anemona, and Maria Teresa Voso

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

5. PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE

Author

Viviana Amato, Stefania Fusani, Cristina Papayannidis, Jacopo Nanni, Antonio Curti, Francesco Marchesi, Maurizio Fanciulli, Giorgia Simonetti, Gerardo Musuraca, Giovanni Marconi, Michele Gottardi, Alessandra Sperotto, Alessandra Rossi, Alessio Maria Edoardo Maraglino, Simona Sammassimo, Federica Gigli, Elisabetta Todisco, Corrado Tarella, Fabio Giglio, and Enrico Derenzini

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

6. P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT

Author

Jon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, Yavuz M. Bilgin, Jens VAN Praet, Julio Dávila-Valls, Sonia Martín-Pérez, Jorge Labrador, Jaap Van Doesum, Iker Falces-Romero, Francesca Farina, Martin Schönlein, Caroline Besson, Verena Petzer, Ildefonso Espigado, Michelina Dargenio, Avinash Aujayeb, Uluhan Sili, Laura Serrano, Laszlo Imre Pinczes, Nick de Jonge, Andrés Soto-Silva, Caterina Buquicchio, Lucia Prezioso, Monia Marchetti, Stef Meers, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Laman Rahimli, Gökçe Melis Çolak, Elena Arellano, Dominik Wolf, Stefanie Gräfe, Emanuele Ammatuna, Caroline Berg Venemyr, Oliver A. Cornely, and Livio Pagano

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

7. P1514: MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY

Author

Jon Salmanton-García, Francesco Marchesi, Barbora Weinbergerová, Caterina Buquicchio, Natasa Čolović, Jens VAN Praet, Philipp Koehler, Iker Falces-Romero, Francesca Farina, Federico Itri, Alessandra Romano, Livio Pagano, and Oliver A. Cornely

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

8. PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM

Author

Francesco Marchesi, Elena Papa, Paolo Falcucci, Svitlana Gumenyuk, Francesca Palombi, Francesco Pisani, Daniela Renzi, Atelda Romano, Antonio Spadea, Giulia Regazzo, Maria Giulia Rizzo, Iole Cordone, Maria Laura Foddai, and Andrea Mengarelli

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

9. PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY

Author

Caterina Buquicchio, Jon Salmanton-García, Francesco Marchesi, Federico Itri, Caroline Besson, Sonia Martín-Pérez, Julio Dávila-Valls, Luana Fianchi, Laman Rahimli, Giuseppe Tarantini, Federica Irene Grifoni, Jorge Labrador, Raul Cordoba, Alberto Lopez-Garcia, Nicola Stefano Fracchiolla, Francesca Farina, Oliver A. Cornely, and Livio Pagano

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

10. Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Author

Jon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, Yavuz M. Bilgin, Jens van Praet, Julio Dávila-Valls, Sonia Martín-Pérez, Jorge Labrador, Jaap van Doesum, Iker Falces-Romero, Francesca Farina, Martin Schönlein, Mathilde Chanut, Verena Petzer, Ildefonso Espigado, Michelina Dargenio, Avinash Aujayeb, Uluhan Sili, Laura Serrano, László Imre Pinczés, Nick de Jonge, Andrés Soto-Silva, Caterina Buquicchio, Lucia Prezioso, Monia Marchetti, Stef Meers, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Laman Rahimli, Gökçe Melis Çolak, Elena Arellano, Dominik Wolf, Stefanie Gräfe, Emanuele Ammatuna, Caroline Berg Venemyr, Oliver A. Cornely, and Livio Pagano

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

12. Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study

Author

Chiara Cattaneo, Alessandro Busca, Doriana Gramegna, Francesca Farina, Anna Candoni, Monica Piedimonte, Nicola Fracchiolla, Chiara Pagani, Maria Ilaria Del Principe, Maria Chiara Tisi, Massimo Offidani, Rosa Fanci, Stelvio Ballanti, Angelica Spolzino, Marianna Criscuolo, Francesco Marchesi, Gianpaolo Nadali, Mario Delia, Marco Picardi, Margherita Sciumé, Valentina Mancini, Attilio Olivieri, Mario Tumbarello, Giuseppe Rossi, and Livio Pagano

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract. Invasive fungal diseases (IFDs) remain a major clinical issue in patients with hematological malignancies (HMs). To confirm the efficacy and safety of the new azole isavuconazole (ISV) in a clinical care setting, we planned a multicenter retrospective study; we collected data on all possible/probable/proven IFDs in patients with HMs treated with ISV in 17 centers. Between July 2016 and November 2018, 128 patients were enrolled, and 122 were fully evaluable. ISV was employed as the 1st line therapy in 43 (35%) patients and as a subsequent therapy in 79 (65%) patients. The response rate was 82/122 patients (67.2%); it was similar when using ISV as a 1st or 2nd line treatment (60.5% vs 70.9%, respectively; p = 0.24). In multivariate analysis, both female sex (OR: 2.992; CI: 1.22–7.34) and induction phase of treatment (OR: 3.953; CI: 1.085–14.403) were predictive of a favorable response. At a median follow-up of 5 months, 43 (35.2%) patients were dead; the 1-year overall survival (OS) was 49.9%. In multivariate analysis, the response to ISV (OR: 0.103; CI: 0.041–0.262) and IFD refractoriness to previous antifungals (OR: 3.413; CI: 1.318–8.838) were statistically significant for OS. Adverse events (AEs) were reported in 15/122 patients (12.3%); grade 3–4 AEs were reported in 5 (4%) and led to ISV discontinuation. Our study confirms the safety and tolerability of ISV, also in diseases other than acute leukemia. Phase of hematological disease, gender and refractoriness to previous antifungals are the main predictive factors for the aforementioned response and outcome.

Published
2019
Full Text
View/download PDF

13. EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19

Author

Livio Pagano, Philipp Koehler, Alessandro Busca, Paolo Corradini, Jon Salmanton-García, Oliver A. Cornely, Francesco Marchesi, Nikolai Klimko, Martin Hoenigl, Francesco Passamonti, and Antonio Pagliuca

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, leukemia, Hematology, Settore MED/15 - MALATTIE DEL SANGUE, Editorial, Epidemiology, medicine, Ready to use, Diseases of the blood and blood-forming organs, RC633-647.5, business, Intensive care medicine, Infection
Published
2021
Full Text
View/download PDF

14. S1637 A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP

Author

Andrea Mengarelli, Nicola Stefano Fracchiolla, Mariagiovanna Cefalo, Mariagrazia Garzia, Francesco Marchesi, Simone Cesaro, Caterina Alati, Michelina Dargenio, L. Melillo, Nunzia Decembrino, Chiara Cattaneo, M.I. Del Principe, Antonio Spadea, Alessandro Busca, Livio Pagano, Domenico Russo, Katia Perruccio, Patrizia Zappasodi, Daniele Armiento, Marianna Criscuolo, and Mario Delia

Subjects
medicine.medical_specialty, Lung, medicine.anatomical_structure, Multicenter study, business.industry, Internal medicine, Medicine, Hematology, business, Antimicrobial
Published
2019
Full Text
View/download PDF

15. PS1267 ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY

Author

Chiara Pagani, Chiara Cattaneo, Nicola Stefano Fracchiolla, Maria Chiara Tisi, Francesco Marchesi, Alessandro Busca, Giuseppe Rossi, Rosa Fanci, Marianna Criscuolo, Mario Delia, Laura Maracci, Monica Piedimonte, Anna Candoni, M.I. Del Principe, Stelvio Ballanti, Mariarita Sciumè, Mario Tumbarello, Gianpaolo Nadali, Angelica Spolzino, Marco Picardi, Francesca Farina, Livio Pagano, and Doriana Gramegna

Subjects
Hematology
Published
2019
Full Text
View/download PDF

16. Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study

Author

Nicola Stefano Fracchiolla, Monica Piedimonte, Valentina Mancini, Anna Candoni, Mario Tumbarello, Margherita Sciumé, Giuseppe Rossi, Livio Pagano, Stelvio Ballanti, Massimo Offidani, Chiara Pagani, Doriana Gramegna, Rosa Fanci, Francesco Marchesi, Maria Ilaria Del Principe, Francesca Farina, Alessandro Busca, Attilio Olivieri, Marco Picardi, Gianpaolo Nadali, Angelica Spolzino, Chiara Cattaneo, Marianna Criscuolo, Maria Chiara Tisi, Mario Delia, Cattaneo, C., Busca, A., Gramegna, D., Farina, F., Candoni, A., Piedimonte, M., Fracchiolla, N., Pagani, C., Principe, M. I. D., Tisi, M. C., Offidani, M., Fanci, R., Ballanti, S., Spolzino, A., Criscuolo, M., Marchesi, F., Nadali, G., Delia, M., Picardi, M., Sciume, M., Mancini, V., Olivieri, A., Tumbarello, M., Rossi, G., and Pagano, L.

Subjects
Response rate (survey), medicine.medical_specialty, Acute leukemia, Multivariate analysis, lcsh:RC633-647.5, business.industry, isavuconazole, Retrospective cohort study, lcsh:Diseases of the blood and blood-forming organs, isavuconazole, hematological malignancies, Hematology, Settore MED/15, Settore MED/17 - MALATTIE INFETTIVE, Article, Discontinuation, Tolerability, Internal medicine, Medicine, Observational study, hematological malignancies, business, Adverse effect
Abstract

Invasive fungal diseases (IFDs) remain a major clinical issue in patients with hematological malignancies (HMs). To confirm the efficacy and safety of the new azole isavuconazole (ISV) in a clinical care setting, we planned a multicenter retrospective study; we collected data on all possible/probable/proven IFDs in patients with HMs treated with ISV in 17 centers. Between July 2016 and November 2018, 128 patients were enrolled, and 122 were fully evaluable. ISV was employed as the 1st line therapy in 43 (35%) patients and as a subsequent therapy in 79 (65%) patients. The response rate was 82/122 patients (67.2%); it was similar when using ISV as a 1st or 2nd line treatment (60.5% vs 70.9%, respectively; p = 0.24). In multivariate analysis, both female sex (OR: 2.992; CI: 1.22–7.34) and induction phase of treatment (OR: 3.953; CI: 1.085–14.403) were predictive of a favorable response. At a median follow-up of 5 months, 43 (35.2%) patients were dead; the 1-year overall survival (OS) was 49.9%. In multivariate analysis, the response to ISV (OR: 0.103; CI: 0.041–0.262) and IFD refractoriness to previous antifungals (OR: 3.413; CI: 1.318–8.838) were statistically significant for OS. Adverse events (AEs) were reported in 15/122 patients (12.3%); grade 3–4 AEs were reported in 5 (4%) and led to ISV discontinuation. Our study confirms the safety and tolerability of ISV, also in diseases other than acute leukemia. Phase of hematological disease, gender and refractoriness to previous antifungals are the main predictive factors for the aforementioned response and outcome.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results